Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rusal shareholders did not approve a candidate from Sual Partners

2/2/24 RUAL

Sber fully opened individuals' access to DFA platform

2/2/24 SBER

Yandex has registered the Fund of Managers in the ATS

2/2/24 YNDX

UAC to present airplanes at the World Defence Show international exhibition

2/2/24 UNAC

Vologda Region terminates agreement with Cosmos Hotel Group

2/2/24 AFKS

Board of Directors of Severstal recommended that dividends be paid for 2023

2/2/24 CHMF

Severstal reports for 2023

2/2/24 CHMF

Severstal's sales in 2023 decreased by 2%

2/2/24 CHMF

Samolet's profit increased by 23%

2/2/24 SMLT

Magnit launched the first order pickup point of the marketplace Magnit Market

2/1/24 MGNT